Novel COMT inhibitor opicapone shows sustained inhibition and improved L-DOPA availability in monkeys
Objective: To evaluate the effect of repeated OPC treatments, COMT inhibition versus plasma opicapone level, dose response of COMT inhibition, and systematic and central bioavailability…Clinical characterization of Pramipexole induced edema and skin reaction in Parkinson’s Disease (PD) after one year of follow up
Objective: We report four patients with PD treated several years with irregular and progressively higher doses of pramipexole who presented with extensive chronic bilateral lower…Effect of dopamine agonists versus levodopa as initial treatment in Parkinson’s Disease
Objective: We evaluated the efficacy of different starting drugs in the treatment of Parkinson's disease (PD), in order to further explore the initial therapy of…Patient and Provider Experiences and Attitudes toward Rytary
Objective: To survey Parkinson’s disease (PD) patients and providers about their experiences using Rytary, an oral extended release carbidopa/levodopa capsule (ER C/L). Background: ER C/L…Five Year Outcomes of a Prospective, Multicenter Trial Evaluating Deep Brain Stimulation with a New Multiple Source, Constant Current Rechargeable System in Parkinson’s Disease
Objective: To evaluate the long term follow up of patients in the VANTAGE Study that employed a Deep Brain Stimulation (DBS) system with multiple independent…
Abstracts from the International Congress of Parkinson’s and Movement Disorders.